secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jazz Pharmaceuticals plc (JAZZ)
CIK:        0001232524
Form:       8-K
Filed at:   2026-02-24T23:59:59+00:00
Accession:  0001232524-26-000012
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jazz Pharma FY2025 revenue $4.3B (+5% YoY); GAAP net loss $356M vs $560M income in 2024
--------------------------------------------------------------------------------

- Total revenues record $4.3B in FY2025 (+5% YoY); Q4 revenue $1.2B (+10% YoY).
- GAAP net loss $356M ($5.84 diluted loss per share) vs prior year income of $560M ($8.65 EPS).
- Non-GAAP adjusted net income $522M ($8.38 EPS) vs $1.35B ($20.65 EPS) in 2024; adjusted down significantly.
- Xywav $1.7B (+12%), Epidiolex $1.1B (+9%) in 2025; Modeyso launch generated $48M.
- 2026 revenue guidance $4.25-$4.50B; sBLA submission for zanidatamab in GEA expected in 1Q26.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1232524/000123252426000012/0001232524-26-000012-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1232524/000123252426000012/jazz-20260224.htm
  HTML page:      https://secwatch.observer/filing/0001232524-26-000012

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer